Puma Biotechnology starts ALISCA-Lung2 Phase II trial with paclitaxel
Puma Biotechnology initiated its ALISCA®-Lung2 Phase II trial (PUMA-ALI-4202; NCT07465757) testing alisertib with paclitaxel in advanced small cell lung cancer.
Story updates
08:08:18 PM UTC
SquawkNews
Puma Biotechnology initiated ALISCA-Lung2, a Phase II, ~50-patient dose-escalation trial of alisertib plus paclitaxel in advanced small cell lung cancer after platinum and immunotherapy. Primary endpoint is safety; secondary endpoints include ORR, DOR, DCR, PFS and OS.Material DetailsContext by AI…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.